Benzene-induced acute myeloid leukemia: A clinician's perspective

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 826-830

  Natelson, Ethan A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; CARCINOGEN; INDUSTRIAL CHEMICAL; PETROLEUM;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RISK; CHEMICAL CARCINOGENESIS; CHEMICAL INDUSTRY; CHROMOSOME ANALYSIS; HUMAN; LEUKEMOGENESIS; OCCUPATIONAL CANCER; OCCUPATIONAL HAZARD; PETROCHEMICAL INDUSTRY; PRIORITY JOURNAL; REVIEW; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 21; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; DEVELOPED COUNTRY; DRUG THERAPY; GENE TRANSLOCATION; GENETICS; HEALTH PERSONNEL ATTITUDE; MYELOID LEUKEMIA; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PATHOLOGY;

ACUTE DISEASE; ATTITUDE OF HEALTH PERSONNEL; BENZENE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; DEVELOPED COUNTRIES; DRUG THERAPY; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PETROLEUM; TRANSLOCATION, GENETIC;

EID: 35748972379     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20934     Document Type: Review

References (79)

1. Williams PDR, Paustenbach DJ. Reconstruction of benzene exposure for the Pliofilm cohort (1936-1976) using Monte Carlo techniques. J Tox Environ Health 2003;66:677-781.
2. Descatha A, Jenabian A, Conso F, et al. Occupational exposures and haematological malignancies: Overview on human recent data. Cancer Causes Control 2005;16:939-953.
3. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemia. Haematologica 1999;84:930-945.
4. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-4191.
5. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Bailliere's Clin Haematol 1996;9:57-85.
6. Pederson-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273-3279.
7. Eastmond DA, Mondrala ST, Hasegawa L. Topoisomerase II inhibition by myeloperoxidase-activated hydroquinone: A potential mechanism underlying the genotoxic and carcinogenic effects of benzene. Clin Biol Interact 2005;153/154:207-216.
8. Whysner J, Reddy MV, Ross PM, et al. Genotoxicity of benzene and its metabolites. Mutation Res 2004;566:99-130.
9. Morgan GJ, Alvares CL. Benzene and the hemopoietic stem cell. Chem Biol Interact 2005;153/154:217-222.
10. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: Challenges and research directions. J Natl Can Inst 1996;88:407-418.
11. Zang L, Eastmond DA, Smith MT. The nature of chromosomal aberrations detected in humans exposed to benzene. Crit Rev Toxicol 2002;32:1-42.
12. Linet MS, Yin S-N, Travis LB, et al. Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Environ Health Perspect 1996;104:1353-1363.
13. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997;79:1548-1551.
14. Larson RA, LeBeau MM, Vardiman JW, et al. Myeloid leukemia after hematotoxins. Environ Health Perspect 1996;104:1303-1307.
15. Mijovic A, Mufti GJ. The myelodysplastic syndromes: Towards a functional classification. Blood Rev 1998;12:73-83.
16. Fagioli F, Cuneo A, Piva N, et al. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer 1992;70:77-85.
17. Hayes RB, Yin S-N, Dosemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. J Natl Can Inst 1997;89:1065-1071.
18. Larson RA, Le Beau MM. Therapy-related myeloid leukaemia: A model for leukemogenesis in humans. Chem Biol Interact 2005;153/154:187-195.
19. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003;102:43-52.
20. Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: Evolving concepts of pathogenesis and treatment. Hematology 2004;9:179-187.
21. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematology 1998;83:71-86.
22. Scheinberg DA, Maslak R Weiss M.Acute leukemias. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. Section 2, Chap. 46.2, pp 2404-2433.
23. Wintrobe MM. Clinical Hematology, 1st ed. Philadelphia: Lea & Febiger; 1942. p663.
24. Kalapos I. Die Wirkung des Benzols bei der Leukämie. Klin Wochen 1935;15:864-867.
25. Beutler E. The treatment of acute leukemia: Past, present, and future. Leukemia 2001;15:658-661.
26. Baker RK, Kurz EU, Pyatt DW, et al. Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα. Blood 2001;98:830-833.
27. Fröhling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 2002;20:2480-2485.
28. Haferlach T, Schnittger S, Kern W, et al. Genetic classification of acute myeloid leukemia (AML). Ann Hematol 2004;83(suppl):S97-S100.
29. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-2333.
30. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-2378.
31. Pulsoni A, Pagano L, Lo Coco R, et al. Clinicobiological features and outcome of acute promyelocyte leukemia occurring as a second tumor: The GIMEMA experience. Blood 2002;100:1972-1976.
32. Appelbaum FR, Le Beau MM, Willman CL. Secondary Leukemia. American Society of Hematology Booklet; 1996. pp 33-47.
33. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv (16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes Chromosomes Cancer 2001;33:395-400.
34. Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res 2007:427-434.
35. Silver RT, Bennett JM, Goldman JM, et al. The third international congress on myeloproliferative and myelodysplastic syndromes. Leuk Res 2007;31:11-17.
36. Catenacci DVT, Schiller GJ. Myelodysplasic (sic) syndromes: A comprehensive review. Blood Rev 2005;19:301-319.
37. Kantarjian H. Myelodysplastic Syndromes (MDS): What is new? Leuk Insights 2006;1(1):1-8.
38. Malcovati L, Giovanni M, Porta D, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
39. Kushner JP, Lee GR, Wintrobe MM, et al. Idiopathic refractory sideroblastic anemia. Clinical and laboratory investigation of 17 patients and review of the literature. Medicine 1971;50:139-159.
40. Cazzola M, Barosi G, Gobbi PG, et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988;71:305-312.
41. Garand R, Gardais J, Bizet M, et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 1992;16:463-468.
42. Strom SS, Gu Y, Gruschkus SK, et al. Risk factors of myelodysplastic syndromes: A case-control study. Leukemia 2005;19:1912-1918.
43. Cortes J. CMML: A biologically distinct myeloproliferative disease. Curr Hematol Rep 2003;2:202-208.
44. Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-1318.
45. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617 F mutation. Blood 2006;108:2173-2181.
46. Irons RD, Lv L, Gross SA, et al. Chronic exposure to benzene results in a unique form of dysplasia. Leuk Res 2005;29:1371-1380.
47. Ruiz MA, Augusto LGS, Vassallo J, et al. Bone marrow morphology in patients with neutropenia due to chronic exposure to organic solvents (benzene): Early lesions. Path Res Pract 1994;190:151-154.
48. Aksoy M, Erdem S, Dinçol G. Types of leukemia in chronic benzene poisoning. A study in thirty-four patients. Acta Haematol 1976;55:65-72.
49. Aksoy M. Different types of malignancies due to occupational exposure to benzene: A review of recent observations in Turkey. Environ Res 1980;23:181-190.
50. Rinsky RA, Hornung RW, Silver SR, et al. Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. Am J Indust Med 2002;42:474-480.
51. Wong O. Investigations of benzene exposure, benzene poisoning and malignancies in China. Reg Toxicol Pharm 2002;35:126-135.
52. Bergsagel DE, Wong O, Bergsagel PL, et al. Benzene and multiple myeloma: Appraisal of the scientific evidence. Blood 1999;94:1174-1182.
53. Wong O, Raabe GK. Cell-type specific leukemia analyses in a combined cohort of more than 208,000 petroleum workers in the United States and the United Kingdom, 1937-1987. Reg Toxicol 1995;21:307-321.
54. Satin KP, Bailey WJ, Newton KL, et al. Updated epidemiological study of workers at two California petroleum refineries, 1950-1995. Occup Environ Med 2002;59:248-256.
55. Lynge E, Andersen A, Nilsson R, et al. Risk of cancer and exposure to gasoline vapors. Am J Epidemiol 1997;145:449-458.
56. Wong O, Harris F, Rosamilia K, et al. An updated mortality study of workers at a petroleum refinery in Beaumont, Texas, 1945-1996. J Occup Environ Med 2001;43:384-401.
57. Lewis RJ, Schnatter AR, Drummond I, et al. Mortality and cancer morbidity in a cohort of Canadian petroleum workers. Occup Environ Med 2003;60:918-928.
58. Graff JJ, Sathiakumar N, Macaluso M, et al. Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality. J Occup Environ Med 2005;47:916-932.
59. Sorahan T, Kinlen LJ, Doll R. Cancer risks in historical UK cohort of benzene exposed workers. Occup Environ Med 2005;62:231-236.
60. Sorahan T, Nichols L, Harrington JM. Mortality of United Kingdom oil refinery and petroleum distribution workers, 1951-1998. Occup Med 2002;52:333-339.
61. Satin KR Wong O, Yuan LA, et al. A 50-year mortality follow-up of a large cohort of oil refinery workers in Texas. J Occup Environ Med 1996;38:492-506.
62. Divine BJ, Hartman CM, Wendt JK. Update of the Texaco mortality study 1947-93. II. Analyses of specific cause of death for white men employed in refining, research, and petrochemicals. Occup Environ Med 1999;56:174-180.
63. Gun RT, Pratt N, Ryan R et al. Update of mortality and cancer incidence in the Australian petroleum industry cohort. Occup Environ Med 2006;63:476-481.
64. Bloemen LJ, Youk A, Bradley TD, et al. Lymphohaematopoietic cancer risk among chemical workers exposed to benzene. Occup Environ Med 2004;61:270-274.
65. Korte JE, Hertz-Picciotto I, Schulz MR, et al. The contribution of benzene to smoking-induced leukemia. Environ Health Perspect 2000;108:333-339.
66. Kane EV, Roman E, Cartwright R, et al. Tobacco and the risk of acute leukemia in adults. Brit J Can 1999;81:1228-1233.
67. Chelghoum Y, Danaila C, Belhabri A, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol 2002;13:1621-1627.
68. Carmona R. The 2004 Surgeon General's report. The Health Consequences of Smoking. Chap 2, p 254. US Department of Health and Human Services.
69. Sandler DP, Shore DL, Anderson JR, et al. Cigarette smoking and risk of acute leukemia: Associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Can Inst 1993;85:1994-2003.
70. Pasqualetti P, Festuccia V, Acitelli P, et al. Tobacco smoking and risk of haematological malignancies in adults: A case-control study. Brit J Haematol 1997;97:659-662.
71. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
72. Hsing AW, Hansson L-E, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993;71:745-750.
73. Brinton LA, Gridley Z, Hoover R, et al. Cancer risk following pernicious anemia. Brit J Cancer 1989;59:810-813.
74. Drabick JJ, Davis BJ, Byrd JC. Concurrent pernicious anemia and myelodysplastic syndrome. Ann Hematol 2001;80:243-245.
75. Rosner F, Lee SL. Down's syndrome and acute leukemia: Myeloblasts or lymphoblastic? Report of forty-three cases and review of the literature. Am J Med 1972;53:203-218.
76. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-2235.
77. Rossi G, Pelizzari AM, Bellotti D, et al. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 2000;14:636-641.
78. Danaei G, Vander Hoorn S, Lopez AD, et al. Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784-1793.
79. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-1912.